hydralazine has been researched along with Obesity in 14 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 8.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 8.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 7.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| "The objectives were two-fold: (1) determine whether the use of hydralazine as antihypertensive therapy during obesity development exacerbated obesity-related cardioacceleration and hormonal abnormalities; (2) determine whether the absence of hypertension in obesity attenuated obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile." | 7.72 | Hydralazine as antihypertensive therapy in obesity-related hypertension. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
| "Hydralazine-treated animals had lower body fat (15." | 5.32 | Hydralazine treatment alters body composition in the rabbit model of obesity. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 4.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 4.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 3.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| "The objectives were two-fold: (1) determine whether the use of hydralazine as antihypertensive therapy during obesity development exacerbated obesity-related cardioacceleration and hormonal abnormalities; (2) determine whether the absence of hypertension in obesity attenuated obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile." | 3.72 | Hydralazine as antihypertensive therapy in obesity-related hypertension. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
| "We compared the effects of long-term treatment with the angiotensin-converting enzyme inhibitor perindopril and triple therapy (hydrochlorothiazide, reserpine, and hydralazine) on the metabolic and renal features in the SHR/N-corpulent (cp) rat, a genetic model of non-insulin-dependent diabetes mellitus and hypertension." | 3.69 | Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. ( Abraham, AA; Michaelis, OE; Scalbert, E; Striffler, JS; Thibault, N; Velasquez, MT, 1997) |
| "The metabolic syndrome is a risk factor for the development of renal and vascular complications." | 1.34 | Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. ( Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2007) |
| "Hydralazine treatment consisted of 6 mg/kg/day and 10 to 14 mg/kg/day for LH and OH, respectively." | 1.33 | Loss of diurnal rhythms of blood pressure and heart rate caused by high-fat feeding. ( Carroll, JF; Strange, T; Thaden, JJ; Wright, AM, 2005) |
| "Hydralazine-treated animals had lower body fat (15." | 1.32 | Hydralazine treatment alters body composition in the rabbit model of obesity. ( Carroll, JF; Cohen, JS; King, JW, 2004) |
| "In order to examine the effect of treatment of mild hypertension of the aged, a 4 year prospective trial was performed in 41 placebo and 38 drug-treated patients with an average age of 76." | 1.27 | The treatment of mild hypertension in the elderly, a prospective study using multiple regression analysis. ( Kuramoto, K; Matsushita, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Yamada, S | 1 |
| Ogura, Y | 1 |
| Inoue, K | 1 |
| Tanabe, J | 1 |
| Sugaya, T | 1 |
| Ohata, K | 1 |
| Nagai, Y | 1 |
| Natsuki, Y | 1 |
| Hoshino, S | 1 |
| Watanabe, S | 1 |
| Ichikawa, D | 1 |
| Kimura, K | 1 |
| Shibagaki, Y | 1 |
| Kamijo-Ikemori, A | 1 |
| Larkin, BP | 2 |
| Nguyen, LT | 2 |
| Hou, M | 2 |
| Glastras, SJ | 2 |
| Chen, H | 2 |
| Faiz, A | 1 |
| Chen, J | 1 |
| Wang, R | 2 |
| Pollock, CA | 2 |
| Saad, S | 2 |
| Dong, YF | 1 |
| Liu, L | 1 |
| Kataoka, K | 1 |
| Nakamura, T | 1 |
| Fukuda, M | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Carroll, JF | 3 |
| King, JW | 2 |
| Cohen, JS | 2 |
| Goossens, GH | 1 |
| Blaak, EE | 1 |
| Saris, WH | 1 |
| van Baak, MA | 1 |
| Thaden, JJ | 1 |
| Wright, AM | 1 |
| Strange, T | 1 |
| Namikoshi, T | 1 |
| Tomita, N | 1 |
| Satoh, M | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Velasquez, MT | 1 |
| Striffler, JS | 1 |
| Abraham, AA | 1 |
| Michaelis, OE | 1 |
| Scalbert, E | 1 |
| Thibault, N | 1 |
| Børsheim, E | 1 |
| Lönnroth, P | 1 |
| Knardahl, S | 1 |
| Jansson, PA | 1 |
| Rahman, JC | 1 |
| Kuramoto, K | 1 |
| Matsushita, S | 1 |
| Slany, J | 1 |
1 review available for hydralazine and Obesity
| Article | Year |
|---|---|
[Cardiac complications in hypertension].
Topics: Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Circulation; Coronary Diseas | 1972 |
1 trial available for hydralazine and Obesity
| Article | Year |
|---|---|
Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects.
Topics: Adipose Tissue; Angiotensin II; Body Weight; Central Nervous System Depressants; Drug Interactions; | 2004 |
12 other studies available for hydralazine and Obesity
| Article | Year |
|---|---|
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats.
Topics: Animals; Citrate (si)-Synthase; Comorbidity; Diabetes Mellitus, Type 2; Electron Transport Complex I | 2022 |
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.
Topics: Albuminuria; Animals; Diet, High-Fat; Disease Models, Animal; Fibrosis; Hydralazine; Inflammation; K | 2022 |
Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet.
Topics: Albuminuria; Animals; Biomarkers; Body Weight; Collagen; Diet, High-Fat; DNA Methylation; Female; Fi | 2021 |
Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.
Topics: Amides; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Experiment | 2010 |
Hydralazine as antihypertensive therapy in obesity-related hypertension.
Topics: Animals; Antihypertensive Agents; Biometry; Blood Pressure; Cardiomegaly; Female; Heart Rate; Hormon | 2004 |
Hydralazine treatment alters body composition in the rabbit model of obesity.
Topics: Adipose Tissue; Animals; Body Composition; Body Water; Body Weight; Disease Models, Animal; Eating; | 2004 |
Loss of diurnal rhythms of blood pressure and heart rate caused by high-fat feeding.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Circadian Rhythm; Dietary Fats; Femal | 2005 |
Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein.
Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Dietary Protei | 2007 |
Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus, Type | 1997 |
No difference in the lipolytic response to beta-adrenoceptor stimulation in situ but a delayed increase in adipose tissue blood flow in moderately obese compared with lean men in the postexercise period.
Topics: Adipose Tissue; Adult; Exercise; Fatty Acids, Nonesterified; Glycerol; Heart Rate; Humans; Hydralazi | 2000 |
Hypertension.
Topics: Antihypertensive Agents; Benzothiadiazines; Cooperative Behavior; Diet Therapy; Diuretics; Humans; H | 1975 |
The treatment of mild hypertension in the elderly, a prospective study using multiple regression analysis.
Topics: Aged; Benzothiadiazines; Blood Pressure; Cholesterol; Diuretics; Female; Humans; Hydralazine; Hypert | 1985 |